EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bicycle Therapeutics's enterprise value is $379.25 Mil.
Bicycle Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $26.98 Mil. Therefore, Bicycle Therapeutics's EV-to-Revenue for today is 14.06.
The historical rank and industry rank for Bicycle Therapeutics's EV-to-Revenue or its related term are showing as below:
BCYC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -5.38 Med: 22.12 Max: 117.67
Current: 14.06
During the past 7 years, the highest EV-to-Revenue of Bicycle Therapeutics was 117.67. The lowest was -5.38. And the median was 22.12.
BCYC's EV-to-Revenue is ranked worse than 62.92% of 1033
companies
in the Biotechnology industry
Industry Median: 7.63
vs BCYC: 14.06
As of today (2024-04-25), Bicycle Therapeutics's stock price is $22.45.
Bicycle Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.80. Therefore, Bicycle Therapeutics's PS Ratio for today is 28.06.
Bicycle Therapeutics EV-to-Revenue Historical Data
The historical data trend for Bicycle Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bicycle Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Bicycle Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's EV-to-Revenue falls into.
Bicycle Therapeutics's current Enterprise Value is $379.25 Mil.
Bicycle Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics's share price for today is $22.45.
Bicycle Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Bicycle Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bicycle Therapeutics (Bicycle Therapeutics) Business Description
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCYC has been successfully added to your 